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Abstract
Introduction:  Asymmetric dimethylarginine (ADMA) is an endogenous
competitive inhibitor of endothelial nitric oxide synthase. Asymmetric
dimethylarginine may influence the process of restenosis after coronary
angioplasty. The aim of the study was to determine if initial plasma ADMA level
could predict restenosis after coronary angioplasty and stenting. 
Material and methods: The study group consisted of 60 consecutive patients
(10 women and 50 men, average age 58.9 ±10.4 years old), who underwent
percutaneous coronary angioplasty with bare metal stenting for stable coronary
artery disease. All patients underwent follow-up coronary angiography after 
a 6-month period. Patients were divided into two groups, one with restenosis
(n = 22), and the other one without restenosis (n = 38). In addition to measuring
acknowledged restenosis risk factors, plasma ADMA level was measured before
initial angiography. 
Results: Asymmetric dimethylarginine plasma level was significantly higher in
the group with restenosis than in the group without restenosis (1.94 ±0.94 μmol/l
vs. 0.96 ±0.67 μmol/l; p < 0.05). L-arginine/ADMA ratio was also decreased in
the group with restenosis, when compared with the group without restenosis
(p < 0.05). Multivariate logistic regression revealed that independent restenosis
risk factors were characterised by an initially high ADMA level (p < 0.01),
advanced age (p < 0.05) and low level of HDL cholesterol (p < 0.05). 
Conclusions: Pre-procedural elevated plasma ADMA level increases the risk of
restenosis in patients who underwent coronary angioplasty and stenting with
bare metal stents.
Key words: asymmetric dimethylarginine, percutaneous coronary intervention, bare
metal stent.
Introduction
Percutaneous coronary intervention (PCI) is widely used in treatment
of coronary artery disease (CAD). Unfortunately, the long-term efficacy of
angioplasty is limited by the recurrent narrowing within the dilated part
of the artery, which is known as restenosis. Based on experimental and
clinical studies, understanding of the phenomenon of restenosis is still
incomplete and needs further elucidation. Data obtained from several
studies were controversial and did not help to determine all the factors
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influencing the process. Injury of the endothelium
within epicardial arteries occurring during
angioplasty is believed to activate the process of
restenosis [1]. Due to this fact it seems reasonable
to search for other factors contributing to
endothelial dysfunction, which may participate in
development and progression of restenosis. 
Asymmetric dimethylarginine (ADMA) is an
endogenous competitive inhibitor of endothelial
nitric oxide synthase (eNOS) [2]. Asymmetric
dimethylarginine is regarded as a new cardio  -
vascular risk factor and it may potentially influence
the process of restenosis occurring after coronary
angioplasty. A strong relationship was shown
between ADMA and CAD, and plasma ADMA level
was higher in patients with a documented CAD
compared to a healthy control group [3].
Simultaneously, Valkonen et al. observed a signi  -
ficant increase in the risk of major cardiovascular
events in middle-aged non-smoking men with
higher plasma ADMA level [4].
The aim of the study was to determine if initial
plasma ADMA level could predict restenosis after
coronary angioplasty and stenting.
Material and methods
The study group consisted of 60 consecutive
patients (10 women and 50 men, average age 58.9
±10.4 years) with stable coronary artery disease who
underwent PCI. All subjects had chronic CCS
(Canadian Cardiovascular Society) class II or III angina
and were treated with simvastatin, in the dose of
20 mg or 40 mg, acetylsalicylic acid 75-150 mg,
angiotensin-converting enzyme inhibitor and 
β-blocker, if possible. Short acting nitroglycerine
was administered only in case of stenocardial pain.
Clinical indications for coronary angiography were
based on the stress treadmill test and symptoms.
Subjects reported that angina was not controlled
by the optimal medical therapy. Patients with
a significantly positive stress treadmill with ST
depressions more than 4 mm and with a low
exercise tolerance (less than about 4 MET) were
qualified for coronary angiography. Additionally,
substantial objective evidence of extensive
ischaemia in echocardiography was taken into
account.
Coronary angiography was performed through
the femoral artery with the help of Judkins’
technique, using a 6 F haemostatic sheath with
Advantax equipment (General Electric, USA). Non-
ionic contrast agents were used only to visualize
the coronary circulation. Epicardial coronary arteries
were visualized with selective coronary angiography
in standard projections. In selected cases standard
projections were supported by individually matched
projections. Coronary angioplasty was performed
when the stenosis of the coronary artery exceeded
70%. Bare metal stents (BMS) were used in all
cases. Patients with drug-eluting stents (DES), and
patients who underwent solely balloon angioplasty
were not included in the study. Only patients after
the implantation of one stent were examined. Stent
implantation was performed after balloon pre-
dilatation with inflation pressure of 12 atm to 
18 atm or with direct stenting. Balloon inflation
lasted between 30 and 40 s in case of balloon pre-
dilatation, and about 20-30 s in case of direct stent
implantation. Maximally three inflations were
accepted. Time and number of inflations, as well as
balloon diameter, were individually adjusted. All
patients who underwent a successful PCI with
residual narrowing not exceeding 20% followed by
BMS in a single coronary artery were qualified for
the study. 
Exclusion criteria for this study included
atherosclerotic lesions which were over 30 mm
long, lesions of the left main coronary artery, ostial
lesions or lesions located in bifurcations, and lesions
located within native coronary arteries except those
of diameter between 2.5 mm and 3.5 mm.
Furthermore, patients with any acute or chronic
inflammatory diseases, as well as patients with
diabetes, malignancies, heart failure, kidney or liver
insufficiency, with massive haemorrhages, acute
myocardial infarctions and with indications for acute
revascularisation or with fatal complications, were
excluded from the study.
In order to assess the final result of the
procedure, angiographic evaluation was performed
immediately after coronary angioplasty. The long-
term result was assessed 6 months after the
procedure, by means of control coronary angio  -
graphy. Restenosis was defined as narrowing within
the vessel lumen at the location of stent
implantation or within 1 cm from the stent margin,
exceeding 50%. Objective evaluation of the vessel
lumen was performed with digital quantitative
coronary angiography (QCA) analysis. Patients with
recurrent vessel narrowing ≥ 50% were included in
the group with restenosis (group I; n = 22). Patients
without stenosis or with narrowing < 50% were
included in the group without restenosis (group II;
n = 38). The recruitment of patients to the specific
group according to the definition of restenosis was
made blindly to ADMA levels.
Venous blood was collected directly before the
procedure. The ethylenediaminetetra-acetate (EDTA)
blood was centrifuged (at speed of 10 000/per
minute); plasma was collected and frozen at the
temperature of –70°C, in order to perform ADMA
measurement by high performance liquid chroma  -
tography (HPLC). Total cholesterol, LDL cholesterol,
HDL cholesterol and triglyceride serum levels were
determined by using commercial tests (Boehringer
Mannheim, Germany).446 Arch Med Sci 3, June / 2011
Informed consent was obtained from each
patient within both study groups. The Bioethical
Committee of Wroclaw Medical University approved
the study.
Statistical analysis was performed with the
Statistica PL 6.0 package (StatSoft, Poland). Average
(x) and standard deviations (SD) concerning
quantitative variables and percentage values for
qualitative variables were measured in the studied
groups. The distribution was verified with the
Shapiro-Wilk W-test. In the case of quantitative
variables with abnormal distribution, a non-
parametric Mann-Whitney U-test was used. To
determine the independent risk factors of
restenosis, multivariate logistic regression analysis
was performed. The analysis involved total, LDL and
HDL cholesterol, triglycerides, ADMA, and the age
of patients. Values of p < 0.05 were accepted as
statistically significant.
Results
The study subgroups with and without
restenosis did not differ as far as demographics,
medications, laboratory parameters and clinical
factors are concerned. Demographics and laboratory
parameters of both groups are presented in Table I.
No significant differences in basic angiographic
parameters reported before and after coronary
angioplasty were observed between group I and
group II (Table II).
In the group with restenosis ADMA plasma
concentration was significantly higher than in the
group without restenosis. L-arginine/ADMA ratio was
also lower in the group with restenosis, compared
to the group without restenosis (Table III).
Multivariate logistic regression revealed that
independent risk factors of restenosis were an
initial high ADMA level [OR = 5.96 (2.45, 11.26); 
p < 0.01], advanced age [OR = 1.02 (1.00, 1.17); 
p < 0.05] and low level of HDL cholesterol [OR =
0.96 (0.76, 0.99); p < 0.05], [OR – odds ratio for unit
change (confidence interval –95%, 95%)]. Plasma
glucose levels were normal and this parameter was
not included in the regression model. 
Discussion
The role of biochemical factors in the
pathogenesis of coronary artery restenosis after
PCI continues to be the subject of multiple
investigations. The analysis is quite difficult due to
the complex character of the phenomenon. Findings
resulting from the experimental environment
frequently have no confirmation in clinical studies.
Earlier studies of this phenomenon were based on
angiographic evaluation of atherosclerotic lesions.
It was proved that long lesions with calcifications,
located within arteries of small diameter and of
type C stenosis are more prone to restenosis. Other
risk factors for restenosis included diabetes
mellitus, unstable coronary heart disease, signi  -
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Parameters Whole group (n = 60) Group I (n = 22) Group II (n = 38) Value of p
Age [years]  58.9 ±10.4 58.6 ±9.6 592 ±10.9 NS
Men [%] 83.7  81.3 84.8 NS
Total cholesterol [mg/dl] 198.9 ±45.5 200.1 ±56.4  198.3 ±39.9 NS
LDL cholesterol [mg/dl] 123.5 ±36.8 119.3 ±44.1 125.2 ±34.2 NS
HDL cholesterol [mg/dl] 45.1 ±9.6 45.2 ±9.9 45.1 ±9.6 NS
Triglycerides [mg/dl] 155.6 ±90.2 184.9 ±114.2 140.9 ±73.2 NS
Previous myocardial infarction [%] 51.7  52.5  50.5  NS
Active smoking [%] 50.0   53.1  48.3  NS
Arterial hypertension [%] 46.7   48.6 43.6  NS
Table I. Study group demographics 
Parameter Group I (n = 22) Group II (n = 38) Value of p
Before angioplasty Reference diameter [mm] 3.0 ±0.2 3.1 ±0.1 NS
Percent stenosis  74.2 ±12.2 74.1 ±13.7 NS
Lesion length [mm] 16.4 ±2.4 16.9 ±1.1 NS
Stent length [mm] 18.2 ±3.9 19.1 ±5.3 NS
Maximal inflation pressure [atm] 15.9 ±3.7 15.4 ±3.1 NS
After angioplasty Percent residual stenosis 12.8 ±10.9 14.7 ±11.8 NS
Table II. Basic angiographic parameters before and after coronary angioplasty Arch Med Sci 3, June / 2011 447
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ficant length of the implanted stent and sub-
optimal result of coronary angioplasty with large
residual stenosis [5].
Patients with diabetes mellitus, acute or chronic
inflammatory disease and with acute coronary
syndrome were excluded from our study. Moreover,
taking the characteristics of anatomy, anthro  -
pometrics and angioplasty procedure into account,
as well as pharmacotherapy, special exclusion
criteria were applied to make the study group
homogeneous. Such restrictive inclusion criteria
limited the influence of various anatomical and
anthropometric factors, as well as the influence of
factors connected with the procedure itself, on the
recurrence of restenosis and on ADMA concen  -
trations. Only bare metal stents were used in our
study, as their influence on the function of the artery
wall is weak in comparison to drug-eluting stents.
Our study is one of the first studies to report that
the initial asymmetric dimethylarginine plasma level
preceding the performance of coronary angioplasty
with stenting increases risk of restenosis after 
6 months. A recent study found similar results in
a group of 105 patients. The levels of ADMA
obtained before the procedure predicted the
development of restenosis and major adverse
cardiac events in patients who underwent elective
PTCA and bare metal stent procedures [6]. 
In the group of patients with restenosis the
initial plasma level of ADMA was significantly higher
(p < 0.01) and the ratio of L-arginine/ADMA was
significantly lower in comparison to patients
without restenosis (p < 0.01). Additionally, logistic
regression analysis revealed that the independent
risk factors of restenosis include ADMA, age and
HDL cholesterol level. 
An earlier study by Lu et al. showed an increased
number of cardiovascular events, including
restenosis, after PCI in patients with increased
plasma ADMA levels [7]. The study revealed the
negative influence of age and the protective role of
HDL cholesterol level on the recurrent narrowing in
the coronary artery after coronary angioplasty [8].
Elevated plasma ADMA level was reported in
patients with traditional cardiovascular risk factors:
endothelial dysfunction, elevated total cholesterol
level, arterial hypertension, impaired glucose
tolerance, and increased intima-media thickness
[9–14]. Asymmetric dimethylarginine – an
endogenous inhibitor of endothelial nitric oxide
(NO) synthase – impairs endothelial NO production,
leading to NO deficiency and increased production
of oxygen free radicals [15, 16]. Endogenous nitric
oxide has anti-inflammatory capabilities, as it
inhibits the interaction between endothelium and
circulating monocytes [17]. Nitric oxide also inhibits
platelet aggregation and their interactions with
endothelium, simultaneously decreasing in vitro
proliferation of vascular smooth muscle cells [18,
19]. Significant damage of the endothelium
resulting from coronary angioplasty stimulates the
smooth vascular muscle [20]. Furthermore, it was
also found in an animal model that the nitric oxide
produced in the endothelium decreases the in vivo
proliferation of smooth muscles in vessels, as well
as the growth of neointima [21]. Decreased
endothelial production of NO in patients with
elevated ADMA levels may accelerate the process
of restenosis. Increased ADMA plasma concen  -
tration is associated with impaired flow-mediated
vasodilation and the progression of atherosclerosis
[14]. Several studies have reported an increased rate
of coronary restenosis in patients with impaired
flow-mediated vasodilatation [22-24]. Increased
plasma ADMA concentrations may also cause the
upregulation of angiotensin-converting enzyme 
and increased oxidative stress by means of angio  -
tensin I receptor [25, 26]. Concentrations of ADMA
obtained before PCI predict the development of
restenosis and major adverse cardiac events.
However, there have been reports not confirming
the predictive value of ADMA levels in acute
coronary syndrome [6, 27].
Further clinical implications for the use of ADMA
levels could be based on the observation that levels
of ADMA obtained before the procedure predict the
development of restenosis and major adverse
cardiac events in patients who underwent PCI and
bare metal stent procedures and thus it may be
applied in such a group of patients.
A limitation of the study is the small number of
participants. The study should be treated as
a preliminary report.
In conclusion, there are several known
mechanisms that may explain acceleration of
restenosis in patients with elevated ADMA levels.
Pre-procedural elevated plasma ADMA level
increases the risk of restenosis in patients who
underwent coronary angioplasty and stenting with
bare metal stents.
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